Spike RBD triple mutant (K417N, E484K and N501Y) SARS-CoV-2(2019nCoV) Pseudotyped virus production and Pseudovirus Based Neutralization Assay

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

GeneMedi pseudotyped virus (pseudovirus) of SARS-COV-2 (2019nCOV) 501Y.V2 lineage

The world is in midst of the COVID-19 pandemic. Recently a new SARS-CoV-2 (2019nCOV)lineage (501Y.V2,B.1.351), characterised by eight lineage-defining mutations in the spike protein (excluding D614G mutation), including three at important residues in the receptor-binding domain (K417N, E484K and N501Y), represents increased transmissibility. This lineage emerged in South Africa and spread rapidly, becoming within weeks the dominant lineage in the Eastern Cape and Western Cape Provinces of South Africa.

Mutations of Spike protein in SARS-COV-2 (2019nCOV) 501Y.V2 lineage(B.1.351) (B.1.351) spread in South Africa

Three of the spike mutations are at key residues in the RBD (N501Y, E484K and K417N), three are in the N-terminal domain (L18F, D80A and D215G) and one is in loop 2 (A701V). Deletion of three amino acids at L242-244L is disputed with a L242H mutation¹.

Figure. Amino acid changes in the spike region of the 190 S501Y.V2 genomes¹

GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) 501Y.V2 lineage

Description

The outbreak of COVID-19, caused by SARS-CoV-2 (2019-nCoV), has been a global public health threat and caught the worldwide concern. GeneMedi has developed SARS-CoV-2 wildtype and mutation variants pseudovirus production system, from which the SARS-CoV-2 wildtype and mutation variants pseudotyped virus can be handled in biosafety level 2 (BSL-2).

GeneMedi develop COVID-19 related SARS-CoV-2 (2019-nCoV)Pseudotyped virus of SARS-CoV-2 Spike Mutation Variants including D614G,S943P,V367F, G476S, V483A, H49Y, Q239K, A831V, P1263L, D839Y/N/E:D839Y,D839N,D839E and so on.

SARS-CoV-2 Pseudotyped virus with Spike D614G mutation:Increasing frequency and global distribution.
SARS-CoV-2 Pseudotyped virus with Spike S943P mutation:It is found only in Belgium
SARS-CoV-2 Pseudotyped virus with Spike V367F mutation:
SARS-CoV-2 Pseudotyped virus with Spike G476S mutation
SARS-CoV-2 Pseudotyped virus with Spike V483A mutation
SARS-CoV-2 Pseudotyped virus with Spike H49Y mutation
SARS-CoV-2 Pseudotyped virus with Spike Q239K mutation
SARS-CoV-2 Pseudotyped virus with Spike A831V mutation
SARS-CoV-2 Pseudotyped virus with Spike P1263L mutation
SARS-CoV-2 Pseudotyped virus with Spike D839Y/N/E-D839Y mutation
SARS-CoV-2 Pseudotyped virus with Spike D839Y/N/E-D839N mutation
SARS-CoV-2 Pseudotyped virus with Spike D839Y/N/E-D839E mutation
SARS-CoV-2 Pseudotyped virus with P2-mutated Spike protein trimer variant (P2-mutant, S1/S2 cleavage site (furin cleavage sequence)-mutant,trimerization modified) mutation
SARS-CoV-2 Pseudotyped virus with Spike of SARS-COV-2 B.1.1.7 lineage mutation
SARS-CoV-2 Pseudotyped virus with Spike(S1+S2) N501Y mutation mutation
SARS-CoV-2 Pseudotyped virus with Spike(S1+S2)-HV 69-70 Deletion mutation(ΔH69/ΔV70) mutation

GeneMedi’s Pseudovirus Based Neutralization Assay (PBNA) is a conventional assay method that is suitable for High-Throughout Screening (HTS) without live virus engaged. The Pseudovirus Based Neutralization Assay can be used for evaluating:

1) Neutralizing antibodies
2) Peptides blockers (peptide inhibitors)
3) Types of Vaccines3
4) Compounds targeting Spike induced cell-fusion.

GeneMedi offers:

1.SARS-CoV-2 Pseudotyped virus packaging and production
2.Effector cells: human ACE2 overexpression stable HEK293T cell lines
3.SARS-CoV-2(2019nCoV) Pseudotyped Virus Based Neutralization Assay service.